Please Wait.....
Report
South Africa Biopharmaceuticals Market - Industry Outlook & Forecast 2023-2028
Market Report I 2023-08-08 I 202 Pages I Arizton Advisory & Intelligence
The South Africa biopharmaceuticals market is expected to grow at a CAGR of 12.30% from 2022 to 2028.
MARKET TRENDS AND DRIVERS
Promising Signs for Local Biopharmaceutical Production in South Africa
The promising signs for local biopharmaceutical production in South Africa reflect a growing interest in developing a robust and self-sufficient pharmaceutical industry. With strong government support, research advancements, collaborative partnerships, and a focus on addressing healthcare demands, the country is poised to make significant strides in biopharmaceuticals. By fostering local production, the South Africa biopharmaceuticals market can improve access to essential medicines, drive healthcare innovation, and contribute to economic development, ultimately benefiting the healthcare sector and the well-being of its population.
Growing Pharmaceutical Industry & Investment Opportunities
The growing South Africa biopharmaceuticals market presents ample investment opportunities for companies and investors. The country's expanding market size, disease burden, government support, local manufacturing focus, robust regulatory environment, and potential for regional market access contribute to its attractiveness as a pharmaceutical investment destination. As the healthcare landscape continues to evolve, companies investing in research, development, and manufacturing capabilities are well-positioned to capitalize on the country's burgeoning pharmaceutical market and improve healthcare outcomes for the South African population and beyond.
Growing Access to CGTs in South Africa
The growing access to cell and gene therapies in South Africa presents a transformative opportunity to revolutionize healthcare and improve patient outcomes. With the potential to address genetic and rare diseases, enhance cancer care, and offer personalized medicine, these therapies are poised to impact healthcare delivery profoundly. As the South Africa biopharmaceuticals market embraces these innovations and establishes supportive policies and infrastructure, the region can position itself at the forefront of biomedical research and become a hub for cutting-edge therapies, unlocking new possibilities for patients and healthcare providers.
Increasing Prevalence of Chronic Diseases & Growing Aging Population
The increasing prevalence of chronic diseases and the growing aging population in South Africa are compelling factors that necessitate a proactive and comprehensive approach to healthcare. Addressing these challenges requires strategic planning, increased investment in healthcare infrastructure, preventive health initiatives, and equitable access to healthcare services. By focusing on these areas, South Africa can improve health outcomes, enhance the quality of life for its citizens, and build a more resilient and sustainable healthcare system to meet future needs.
Increasing Focus on Precision Medicine
The increasing focus on precision medicine in South Africa marks a transformative shift in healthcare, offering the potential to revolutionize patient care and disease management. By leveraging genomic data, health informatics, and targeted therapies, precision medicine aims to deliver more effective, personalized, and patient-centric healthcare solutions. As the region continues to advance its precision medicine capabilities, integrating genomic insights into clinical practice holds the promise of improving health outcomes, reducing healthcare costs, and enhancing the quality of life for the population.
SEGMENTATION INSIGHTS
INSIGHTS BY PRODUCT
The South Africa biopharmaceuticals market by product segments as vaccines, monoclonal antibodies, recombinant proteins & hormones, and tissue, cell & gene therapies. The vaccines segment accounted for the largest segmental share. Vaccines are pivotal in public health, preventing and controlling infectious diseases that threaten communities worldwide. In South Africa, vaccines are a cornerstone of the biopharmaceuticals market, providing essential protection against various infectious diseases and contributing to the nation's efforts to improve public health and healthcare outcomes. Government initiatives and partnerships with international organizations have been instrumental in driving vaccine development and distribution in South Africa. The country's government, WHO, and other global health entities have implemented immunization programs targeting various age groups and high-risk populations.
Segmentation by Product
- Vaccines
- Monoclonal Antibodies
- Recombinant Proteins & Hormones
- Tissue, Cell & Gene Therapies
INSIGHTS BY THERAPY AREA
The infectious diseases by therapy area segment accounted for the largest South Africa biopharmaceuticals market share. Infectious diseases have long been a significant public health concern in South Africa, posing challenges to the healthcare system and population. The country's biopharmaceutical market is crucial in addressing these challenges by providing innovative and effective treatments and preventive measures against infectious diseases. The biopharmaceuticals market in the region has played a pivotal role in addressing infectious diseases through developing and distributing vaccines, antiviral drugs, antibiotics, and other therapeutics. Antiretroviral therapy (ART) has been a game-changer in managing HIV/AIDS, improving HIV-positive individuals' quality of life and life expectancy.
Segmentation by Therapy Area
- Infectious Diseases
- Diabetes
- Oncology
- Inflammation & Immunology
- Other Therapy Areas
VENDOR LANDSCAPE
The South Africa biopharmaceuticals market is a dynamic and rapidly growing sector, driven by increasing healthcare needs, a rising burden of chronic diseases, and advancements in medical research and biotechnology. The industry is characterized by intense competition among pharmaceutical companies vying for a share in this lucrative and critical industry.
Key Company Profiles
- AbbVie
- F. Hoffmann-la Roche
- GSK
- Johnson & Johnson
- Merck & Co.
- Novartis
- Novo Nordisk
- Pfizer
- Sanofi
Other Prominent Vendors
- Amgen
- Biocon
- Biogen
- Cipla
- Eli Lilly and Company
- Teva Pharmaceutical Industries
- Viatris
KEY QUESTIONS ANSWERED:
1. How big is the South African biopharmaceuticals market?
2. What is the South Africa biopharmaceuticals market's projected growth rate?
3. Who are the key players in the South Africa biopharmaceuticals market?
4. What are the rising trends in the South African biopharmaceuticals market?
5. Which therapy area holds the most significant South African biopharmaceuticals market share?
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY PRODUCT
4.3.2 MARKET SEGMENTATION BY THERAPY AREA
4.3.3 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 PREMIUM INSIGHTS
7.1 OVERVIEW
7.1.1 PRODUCT SEGMENTATION INSIGHTS
7.1.2 THERAPY AREA SEGMENTATION INSIGHTS
8 INTRODUCTION
8.1 BIOPHARMACEUTICALS: OVERVIEW
8.1.1 GLOBAL BIOPHARMACEUTICALS MARKET SCENARIO
8.1.2 SOUTH AFRICA BIOPHARMACEUTICALS MARKET SCENARIO
8.2 BIOPHARMA MANUFACTURING
8.2.1 ADVANCES IN BIOPHARMA MANUFACTURING
8.2.2 IMPORTANCE OF SINGLE-USE BIOPROCESSING IN BIOLOGICS MANUFACTURING
8.3 REGULATORY SCENARIO OF BIOPHARMACEUTICALS IN SOUTH AFRICA
8.4 REIMBURSEMENT SCENARIO OF BIOPHARMACEUTICALS IN SOUTH AFRICA
8.5 SUPPLY CHAIN OF BIOPHARMACEUTICALS
8.6 COVID-19 IMPACT ANALYSIS
8.6.1 POSSIBLE IMPACT OF THE COVID-19 PANDEMIC ON THE BIOPHARMACEUTICALS MARKET
8.6.2 PRE-COVID & POST-COVID MARKET SCENARIO OF BIOPHARMACEUTICALS
9 MARKET OPPORTUNITIES & TRENDS
9.1 PROMISING SIGNS FOR LOCAL BIOPHARMACEUTICAL PRODUCTION IN SOUTH AFRICA
9.2 INCREASED ADOPTION OF BIOSIMILARS
9.3 GROWTH OF PHARMACEUTICAL INDUSTRY & INVESTMENT OPPORTUNITIES
9.4 INCREASED ACCESS TO CGT IN SOUTH AFRICA
10 MARKET GROWTH ENABLERS
10.1 PREVALENCE OF CHRONIC DISEASES & LARGE AGING POPULATION
10.1.1 TOP CHRONIC DISEASES IN SOUTH AFRICA
10.2 INCREASED FOCUS ON PRECISION MEDICINE
10.3 BIOLOGICS UPTAKE & POTENTIAL IN SOUTH AFRICA
11 MARKET RESTRAINTS
11.1 LACK OF MANUFACTURING CAPABILITIES
11.2 HIGH DEVELOPMENT COST OF BIOLOGICS
11.3 POOR PATIENT ACCEPTANCE & ACCESS TO BIOLOGICS
12 MARKET LANDSCAPE
12.1 MARKET OVERVIEW
12.2 MARKET SIZE & FORECAST
12.3 MARKET OPPORTUNITY
12.3.1 MARKET OPPORTUNITY BY PRODUCT
12.3.2 MARKET OPPORTUNITY BY THERAPY AREA
12.4 FIVE FORCES ANALYSIS
12.4.1 THREAT OF NEW ENTRANTS
12.4.2 BARGAINING POWER OF SUPPLIERS
12.4.3 BARGAINING POWER OF BUYERS
12.4.4 THREAT OF SUBSTITUTES
12.4.5 COMPETITIVE RIVALRY
13 PRODUCT
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 VACCINES
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.4 MONOCLONAL ANTIBODIES
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.5 RECOMBINANT PROTEINS & HORMONES
13.5.1 MARKET OVERVIEW
13.5.2 MARKET SIZE & FORECAST
13.6 TISSUE, CELL & GENE THERAPIES
13.6.1 MARKET OVERVIEW
13.6.2 MARKET SIZE & FORECAST
14 THERAPY AREA
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 INFECTIOUS DISEASES
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.4 DIABETES
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.5 ONCOLOGY
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST
14.6 INFLAMMATION & IMMUNOLOGY
14.6.1 MARKET OVERVIEW
14.6.2 MARKET SIZE & FORECAST
14.7 OTHER THERAPY ARAES
14.7.1 MARKET OVERVIEW
14.7.2 MARKET SIZE & FORECAST
15 COMPETITIVE LANDSCAPE
15.1 COMPETITION OVERVIEW
15.1.1 KEY HIGHLIGHTS OF SOUTH AFRICA BIOPHARMACEUTICALS MARKET
15.2 MARKET SHARE ANALYSIS
15.2.1 ABBVIE
15.2.2 F. HOFFMANN-LA ROCHE
15.2.3 GSK
15.2.4 JOHNSON & JOHNSON
15.2.5 MERCK & CO.
15.2.6 NOVARTIS
15.2.7 NOVO NORDISK
15.2.8 PFIZER
15.2.9 SANOFI
16 KEY COMPANY PROFILES
16.1 ABBVIE
16.1.1 BUSINESS OVERVIEW
16.1.2 PRODUCT OFFERINGS
16.1.3 KEY STRATEGIES
16.1.4 KEY STRENGTHS
16.1.5 KEY OPPORTUNITIES
16.2 F. HOFFMANN-LA ROCHE
16.2.1 BUSINESS OVERVIEW
16.2.2 PRODUCT OFFERINGS
16.2.3 KEY STRATEGIES
16.2.4 KEY STRENGTHS
16.2.5 KEY OPPORTUNITIES
16.3 GSK
16.3.1 BUSINESS OVERVIEW
16.3.2 PRODUCT OFFERINGS
16.3.3 KEY STRATEGIES
16.3.4 KEY STRENGTHS
16.3.5 KEY OPPORTUNITIES
16.4 JOHNSON & JOHNSON
16.4.1 BUSINESS OVERVIEW
16.4.2 PRODUCT OFFERINGS
16.4.3 KEY STRATEGIES
16.4.4 KEY STRENGTHS
16.4.5 KEY OPPORTUNITIES
16.5 MERCK & CO.
16.5.1 BUSINESS OVERVIEW
16.5.2 PRODUCT OFFERINGS
16.5.3 KEY STRATEGIES
16.5.4 KEY STRENGTHS
16.5.5 KEY OPPORTUNITIES
16.6 NOVARTIS
16.6.1 BUSINESS OVERVIEW
16.6.2 PRODUCT OFFERINGS
16.6.3 KEY STRATEGIES
16.6.4 KEY STRENGTHS
16.6.5 KEY OPPORTUNITIES
16.7 NOVO NORDISK
16.7.1 BUSINESS OVERVIEW
16.7.2 PRODUCT OFFERINGS
16.7.3 KEY STRATEGIES
16.7.4 KEY STRENGTHS
16.7.5 KEY OPPORTUNITIES
16.8 PFIZER
16.8.1 BUSINESS OVERVIEW
16.8.2 PRODUCT OFFERINGS
16.8.3 KEY STRATEGIES
16.8.4 KEY STRENGTHS
16.8.5 KEY OPPORTUNITIES
16.9 SANOFI
16.9.1 BUSINESS OVERVIEW
16.9.2 PRODUCT OFFERINGS
16.9.3 KEY STRATEGIES
16.9.4 KEY STRENGTHS
16.9.5 KEY OPPORTUNITIES
17 OTHER PROMINENT VENDORS
17.1 AMGEN
17.1.1 BUSINESS OVERVIEW
17.1.2 PRODUCT OFFERINGS
17.2 BIOCON
17.2.1 BUSINESS OVERVIEW
17.2.2 PRODUCT OFFERINGS
17.3 BIOGEN
17.3.1 BUSINESS OVERVIEW
17.3.2 PRODUCT OFFERINGS
17.4 CIPLA
17.4.1 BUSINESS OVERVIEW
17.4.2 PRODUCT OFFERINGS
17.5 ELI LILLY AND COMPANY
17.5.1 BUSINESS OVERVIEW
17.5.2 PRODUCT OFFERINGS
17.6 TEVA PHARMACEUTICAL INDUSTRIES
17.6.1 BUSINESS OVERVIEW
17.6.2 PRODUCT OFFERINGS
17.7 VIATRIS
17.7.1 BUSINESS OVERVIEW
17.7.2 PRODUCT OFFERINGS
18 REPORT SUMMARY
18.1 KEY TAKEAWAYS
18.2 STRATEGIC RECOMMENDATIONS
19 QUANTITATIVE SUMMARY
19.1 MARKET BY PRODUCT
19.2 MARKET BY THERAPY AREA
20 APPENDIX
20.1 ABBREVIATIONS
LIST OF EXHIBITS
EXHIBIT 1 SEGMENTATION OF SOUTH AFRICA BIOPHARMACEUTICALS MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2022
EXHIBIT 3 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY PRODUCT: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 4 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY THERAPY AREA: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 5 GLOBAL BIOPHARMACEUTICALS MARKET 2022-2028 ($ BILLION)
EXHIBIT 6 SUMMARY OF THE BIOLOGICAL MEDICINES EVALUATION AND RESEARCH UNIT (BMERU) REGULATORY REQUIREMENTS FOR BIOLOGIC & BIOSIMILAR COMPOUNDS IN SOUTH AFRICA
EXHIBIT 7 COMPARISON OF REQUIREMENTS FOR REGISTRATION OF A BIOSIMILAR & REFERENCE MEDICINAL PRODUCT
EXHIBIT 8 IMPACT OF PROMISING SIGNS FOR LOCAL BIOPHARMACEUTICAL PRODUCTION IN SOUTH AFRICA
EXHIBIT 9 IMPACT OF INCREASED ADOPTION OF BIOSIMILARS
EXHIBIT 10 IMPACT OF GROWTH OF PHARMACEUTICAL INDUSTRY & INVESTMENT OPPORTUNITIES
EXHIBIT 11 IMPACT OF INCREASED ACCESS TO CGT IN SOUTH AFRICA
EXHIBIT 12 IMPACT OF PREVALENCE OF CHRONIC DISEASES & LARGE AGING POPULATION
EXHIBIT 13 IMPACT OF INCREASED FOCUS ON PRECISION MEDICINE
EXHIBIT 14 IMPACT OF BIOLOGICS UPTAKE & POTENTIAL IN SOUTH AFRICA
EXHIBIT 15 IMPACT OF LACK OF MANUFACTURING CAPABILITIES
EXHIBIT 16 IMPACT OF HIGH DEVELOPMENT COST OF BIOLOGICS
EXHIBIT 17 IMPACT OF POOR PATIENT ACCEPTANCE & ACCESS TO BIOLOGICS
EXHIBIT 18 SOUTH AFRICA BIOPHARMACEUTICALS MARKET 2022-2028 ($ MILLION)
EXHIBIT 19 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY PRODUCT: MARKET OPPORTUNITY OVERVIEW
EXHIBIT 20 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY THERAPY AREA: MARKET OPPORTUNITY OVERVIEW
EXHIBIT 21 FIVE FORCES ANALYSIS 2022
EXHIBIT 22 INCREMENTAL GROWTH BY PRODUCT 2022 & 2028
EXHIBIT 23 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY PRODUCT 2022-2028: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 24 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY PRODUCT 2022-2028: ABSOLUTE GROWTH (%)
EXHIBIT 25 SOUTH AFRICA VACCINES MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 26 SOUTH AFRICA VACCINES MARKET 2022-2028 ($ MILLION)
EXHIBIT 27 SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 28 SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET 2022-2028 ($ MILLION)
EXHIBIT 29 SOUTH AFRICA RECOMBINANT PROTEINS & HORMONES MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 30 SOUTH AFRICA RECOMBINANT PROTEINS & HORMONES MARKET 2022-2028 ($ MILLION)
EXHIBIT 31 SOUTH AFRICA TISSUE, CELL & GENE THERAPIES MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 32 SOUTH AFRICA TISSUE, CELL & GENE THERAPIES MARKET 2022-2028 ($ MILLION)
EXHIBIT 33 INCREMENTAL GROWTH BY THERAPY AREA 2022 & 2028
EXHIBIT 34 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY THERAPY AREA 2022-2028: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 35 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY THERAPY AREA 2022-2028: ABSOLUTE GROWTH (%)
EXHIBIT 36 SOUTH AFRICA INFECTIOUS DISEASES BIOPHARMACEUTICALS MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 37 SOUTH AFRICA INFECTIOUS DISEASES BIOPHARMACEUTICALS MARKET 2022-2028 ($ MILLION)
EXHIBIT 38 SOUTH AFRICA DIABETES BIOPHARMACEUTICALS MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 39 SOUTH AFRICA DIABETES BIOPHARMACEUTICALS MARKET 2022-2028 ($ MILLION)
EXHIBIT 40 SOUTH AFRICA ONCOLOGY BIOPHARMACEUTICALS MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 41 SOUTH AFRICA ONCOLOGY BIOPHARMACEUTICALS MARKET 2022-2028 ($ MILLION)
EXHIBIT 42 SOUTH AFRICA INFLAMMATION & IMMUNOLOGY BIOPHARMACEUTICALS MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 43 SOUTH AFRICA INFLAMMATION & IMMUNOLOGY BIOPHARMACEUTICALS MARKET 2022-2028 ($ MILLION)
EXHIBIT 44 SOUTH AFRICA OTHER THERAPY AREAS BIOPHARMACEUTICALS MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 45 SOUTH AFRICA OTHER THERAPY AREAS BIOPHARMACEUTICALS MARKET 2022-2028 ($ MILLION)
EXHIBIT 46 VENDORS THAT OFFER COMMERCIAL BIOPHARMACEUTICALS: MARKET DOMINANCE ANALYSIS
EXHIBIT 47 VENDORS THAT OFFER COMMERCIAL BIOPHARMACEUTICALS: CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 48 ABBVIE: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 49 ABBVIE: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 50 F. HOFFMANN-LA ROCHE: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 51 F. HOFFMANN-LA ROCHE: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 52 F. HOFFMANN-LA ROCHE: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 53 GSK: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 54 GSK: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 55 JOHNSON & JOHNSON: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 56 JOHNSON & JOHNSON: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 57 JOHNSON & JOHNSON: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 58 JOHNSON & JOHNSON: REVENUE BY GEOGRAPHIC REGION 2022 ($ BILLION)
EXHIBIT 59 MERCK & CO.: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 60 MERCK & CO.: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 61 MERCK & CO.: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 62 MERCK & CO.: REVENUE BY GEOGRAPHIC REGION 2022 ($ BILLION)
EXHIBIT 63 NOVARTIS: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 64 NOVARTIS: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 65 NOVARTIS: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 66 NOVARTIS: REVENUE BY GEOGRAPHY 2022 ($ BILLION)
EXHIBIT 67 NOVO NORDISK: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 68 NOVO NORDISK: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 69 PFIZER: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 70 PFIZER: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 71 PFIZER: REVENUE BY BUSINESS SEGMENT 2021 ($ BILLION)
EXHIBIT 72 PFIZER: REVENUE BY GEOGRAPHIC REGION 2021 ($ BILLION)
EXHIBIT 73 SANOFI: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 74 SANOFI: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 75 SANOFI: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 76 SANOFI: REVENUE BY GEOGRAPHIC REGION 2022 ($ BILLION)
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2016-2022
TABLE 3 SOUTH AFRICA: OVERVIEW
TABLE 4 SUMMARY OF CROSS-COUNTRY ANALYSIS
TABLE 5 EFFECTS OF BIOSIMILAR LAUNCH ON ORIGINATOR STANDARD UNIT PRICE IN SOUTH AFRICA USING AVERAGE PRICE PER MOLECULE
TABLE 6 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY PRODUCT: MARKET SIZE 2022 & 2028 ($ MILLION)
TABLE 7 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY THERAPY AREA: MARKET SIZE 2022 & 2028 ($ MILLION)
TABLE 8 MABS APPROVED IN SOUTH AFRICA
TABLE 9 ABBVIE: MAJOR PRODUCT OFFERINGS
TABLE 10 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS
TABLE 11 GSK: MAJOR PRODUCT OFFERINGS
TABLE 12 JOHNSON & JOHNSON: MAJOR PRODUCT OFFERINGS
TABLE 13 MERCK & CO.: MAJOR PRODUCT OFFERINGS
TABLE 14 NOVARTIS: MAJOR PRODUCT OFFERINGS
TABLE 15 NOVO NORDISK: MAJOR PRODUCT OFFERINGS
TABLE 16 PFIZER: MAJOR PRODUCT OFFERINGS
TABLE 17 SANOFI: MAJOR PRODUCT OFFERINGS
TABLE 18 AMGEN: MAJOR PRODUCT OFFERINGS
TABLE 19 BIOCON: MAJOR PRODUCT OFFERINGS
TABLE 20 BIOGEN: MAJOR PRODUCT OFFERINGS
TABLE 21 CIPLA: MAJOR PRODUCT OFFERINGS
TABLE 22 ELI LILLY AND COMPANY: MAJOR PRODUCT OFFERINGS
TABLE 23 TEVA PHARMACEUTICAL INDUSTRIES: MAJOR PRODUCT OFFERINGS
TABLE 24 VIATRIS: MAJOR PRODUCT OFFERINGS
TABLE 25 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY PRODUCT 2022-2028 ($ BILLION)
TABLE 26 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY PRODUCT 2022-2028 (%)
TABLE 27 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY THERAPY AREA 2022-2028 ($ BILLION)
TABLE 28 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY THERAPY AREA 2022-2028 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security